Indegene Reports Strong Q1 FY27, Highlights Revenue Growth and Significant Rise in Profitability
Indegene, a strategic operating partner to the global life sciences industry, announced its financial results for the quarter ended June 30, 2026. The company reported robust performance across key metrics, including substantial year-over-year revenue growth and a marked increase in profit after tax (PAT).The firm recorded revenue of ₹ 10,631M ($112.5M) for the quarter. This represents a 39.7% year-on-year (YoY) growth in INR terms, or 26.5% YoY when measured in USD. Key operational achievements include expanding its active client base by 14 sequentially to 105 clients. Furthermore, the number of customers in the $10M+ range increased by 2 sequentially, reaching 12.
Financial performance metrics for the quarter included EBITDA of ₹ 1,795M, translating to a margin of 16.9%. Profit after tax stood at ₹ 1,162M, achieving a profit margin of 10.9%. Revenue per Employee (RPE) also saw improvement, reaching $77.1K, which the company stated was the highest among its peers.
The financial figures for Indegene across three quarters are detailed below:
| Particulars | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 |
|---|---|---|---|
| Revenue from operations (INR) | 10,631 | 10,034 | 7,608 |
| Revenue from operations ($M) | 112.5 | 109.7 | 88.9 |
| YoY revenue growth from operations (%) | 39.7% | 32.8% | 12.5% |
| EBITDA (₹ M) | 1,795 | 1,648 | 1,536 |
| EBITDA margin (%) | 16.9% | 16.4% | 20.2% |
| Profit after tax (₹ M) | 1,162 | 797 | 1,164 |
| Profit margin (%) | 10.9% | 7.9% | 15.3% |
Suhas Prabhu, CFO of Indegene, commented on the results for Q1FY27, noting that the revenue growth in INR terms (39.7%) and USD (26.5%) was significant. He stated that the expansion of the active client base reflected investments made last year to strengthen the sales and go-to-market teams. Prabhu added that profitability improved alongside growth, with sequential expansions seen in both EBITDA and PAT margins. He expects operating leverage to improve further and profitability to strengthen during the second half of the fiscal year as current engagements scale.
About Indegene
Indegene Limited serves as a strategic operating partner to the global life sciences industry. The company manages commercial, medical, R&D, and safety operations throughout the product lifecycle for the world's top 20 biopharma companies. By integrating technology into operations, Indegene helps clients deliver measurable outcomes in regulated environments by combining deep life sciences expertise with AI-embedded platforms and governed operating models.
INDGN Stock Price Movement
Indegene Limited shares today slipped by 1.80% to settle at ₹514.70, dropping ₹9.40 from the previous close. The equity saw a trading volume of 555,545 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.